Innovent Biologics, Inc. (HKG:1801)
Hong Kong · Delayed Price · Currency is HKD | Market Cap | 170.70B +6.5% |
| Revenue (ttm) | 18.13B +37.5% |
| Net Income | 1.42B +8.8% |
| EPS | 0.80 +3.1% |
| Shares Out | 1.74B |
| PE Ratio | 122.05 |
| Forward PE | 46.90 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 16,809,726 |
| Open | 95.15 |
| Previous Close | 95.90 |
| Day's Range | 94.80 - 99.35 |
| 52-Week Range | 69.55 - 112.70 |
| Beta | 0.25 |
| Analysts | Strong Buy |
| Price Target | 129.29 (+31.86%) |
| Est. Earnings | Nov 25, 2026 |
About Innovent Biologics
Innovent Biologics, Inc., a biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People’s Republic of China, the United States, Europe, and internationally. The company discovers, develops, manufactures, and commercializes monoclonal antibodies and other drugs for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and metabolic diseases. Its commercial stage product portfolio includes TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimum... [Read more]
Analyst Summary
According to 30 analysts, the average rating for 1801 stock is "Strong Buy." The 12-month stock price target is $129.29, which is an increase of 31.86% from the latest price.
News
Innovent Reports Updated Phase 1 Data For IBI3003 In Relapsed/Refractory Multiple Myeloma
(RTTNews) - Innovent Biologics, Inc. (1801.HK), a biopharmaceutical company, announced updated Phase 1 clinical data for IBI3003 in patients with relapsed or refractory multiple myeloma (R/R MM), pres...
Innovent's Jaypirca Gets Expanded NMPA Approval For CLL/SLL
(RTTNews) - Innovent Biologics, Inc. (IVBXF) announced that China's National Medical Products Administration (NMPA) has approved Jaypirca (pirtobrutinib) as a monotherapy for adults with chronic lymph...
Innovent Biologics announces China NMPA approves Jaypirca for new indication
Innovent Biologics (IVBXF) announced that the China National Medical Products Administration has approved Jaypirca, a non-covalent Bruton tyrosine kinase inhibitor, as a monotherapy for the treatment ...
Jaypirca® (pirtobrutinib) Approved in China for a New Indication in Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) Across All Lines of Therapy
SAN FRANCISCO and SUZHOU, China, Sept. 28, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercial...
Innovent Expands Phase 3 IBI363 Study To Non-Squamous Lung Cancer; Stock Down
(RTTNews) - Innovent Biologics, Inc. (1801.HK), a biopharmaceutical company focused on developing therapies across oncology and other major diseases, announced the expansion of the global Phase 3 Mars...
Innovent Biologics announces expansion of global Phase 3 MarsLight-11 trial
Innovent Biologics (IVBXF) announces expansion of the global Phase 3 MarsLight-11 trial, which is evaluating IBI363 in patients with squamous non-small cell lung cancer, NSCLC, whose disease has progr...
Altruist Biologics' Suzhou Facility Clears EMA GMP Inspection
(RTTNews) - Altruist Biologics, a contract development and manufacturing organization (CDMO) and wholly owned subsidiary of Innovent Biologics (1801.HK,IVBXF), announced that its commercial manufactur...
Innovent to Present New Clinical Data of Next-gen IO and ADC Pipeline at the 2026 ESMO Annual Meeting
SAN FRANCISCO and SUZHOU, China, Sept. 23, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commerciali...
Chinese biopharma stocks jump as U.S. weighs keeping door open to drug deals
Chinese biopharma stocks advanced Monday, with Innovent Biologics jumping 7% and Akeso up 8% after a report that the U.S. may allow most drug licensing deals with Chinese firms to continue. The propo...
Innovent Biologics Earnings release: H1 2026
Innovent Biologics released its H1 2026 earnings on August 25, 2026, summarizing the period's financial results.
Innovent Biologics Slides: H1 2026
Innovent Biologics has posted slides in relation to its H1 2026 quarterly earnings report, which was published on August 25, 2026.
Innovent Biologics Quarterly report: H1 2026
Innovent Biologics has published its H1 2026 quarterly earnings report on August 25, 2026.
Innovent Biologics and Daiichi Sankyo Enter Exclusive Agreement for VANFLYTA® Commercialization in China
Collaboration to accelerate access to Vanflyta® for patients with newly diagnosed FLT3-ITD positive AML SAN FRANCISCO and SUZHOU, China, Aug. 9, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (01801.HK...
Spero licenses Innovent's experimental immune disease drug for up to $1.1 billion
Spero Therapeutics has licensed rights outside Greater China to develop and commercialize Innovent Biologics' experimental autoimmune disease treatment in a deal worth up to about $1.1 billion, the ...
Spero Therapeutics, Innovent Biologics enter license agreement for SP001
Spero Therapeutics (SPRO) and Innovent Biologics (IVBXF) announced an exclusive license agreement for SP001, a third-generation Fc-silent anti-CD40L antibody. Spero will receive exclusive rights to de...
Innovent Biologics, Eli Lilly enters Verzen distribution and promotion agreement
Innovent Biologics (IVBXF) and Eli Lilly (LLY) jointly announced that they have entered into a distribution and promotion agreement regarding Lilly’s CDK4 & 6 inhibitor Verzenios in mainland China. In...
China's Innovent Biologics gains commercialization rights for Eli Lilly breast cancer drug
Innovent Biologics has entered into an agreement that grants it sole commercialization rights for Eli Lilly's breast cancer drug Verzenios in mainland China, the Chinese drugmaker said Tues...
Pfizer, Innovent GLP-1 drugs pass China insurance preliminary review
Pfizer's GLP-1 drug Ecnoglutide and Innovent Biologics' mazdutide injection have passed a preliminary review to be potentially included in China's basic medical insurance drug catalogue, a ...
Innovent's Partner Ollin Biosciences Announces Oversubscribed $330 Million Series B Financing to Advance Global Phase 3 Development of IBI324 (OLN324) in DME and Wet AMD; Studies Commencing in Second Half of 2026
SAN FRANCISCO and SUZHOU, China, June 24, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commerciali...
Innovent Biologics Announces First Patient Dosed in a Phase 3 Clinical Trial of IBI3003(GPRC5D/BCMA/CD3 Tri-specific Antibody) for the Treatment of Multiple Myeloma
SAN FRANCISCO and SUZHOU, China, June 21, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializ...
2026 ADA | Innovent Presents Multiple Clinical and Preclinical Results of Next-Generation Obesity & Metabolic Pipeline
SAN FRANCISCO and SUZHOU, China, June 8, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercialize...
World's First CLDN18.2 ADC for Regulatory Review: Innovent Biologics Announces IBI343 (arcotatug tavatecan) Met Primary Endpoint in International Phase 3 Study in Advanced Refractory Gastric Cancer and NDA Accepted by China NMPA
SAN FRANCISCO and SUZHOU, China, June 4, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercialize...
Innovent Biologics announces results from PoC study of IBI363
Innovent Biologics (IVBXF) announced the preliminary results from a PoC clinical study of its global first-in-class PD-1/IL-2alpha-bias bispecific fusion protein IBI363 plus chemotherapy in the first-...
2026 ASCO | Innovent Presents Preliminary PoC Data of IBI363 (TAK-928) PD-1/IL-2α-bias bispecific fusion protein) in First-line Advanced NSCLC
IBI363 in combination with chemotherapy demonstrated encouraging efficacy signals and manageable safety in the first-line treatment of NSCLC with PD-L1 negative or low expression . The 3→ 1.5 mg/kg do...
2026 ASCO | Innovent Presents Long-Term Follow-up Results from the PoC Study of IBI363 (TAK-928) (PD-1/IL-2α-bias bispecific fusion protein), Showing Robust Survival Benefits in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer
After long-term follow-up, IBI363 monotherapy demonstrated strong overall survival (OS) with a long tail effect in IO-resistant squamous NSCLC and adenoNSCLC IBI363 has entered a global Phase 3 clinic...